Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 9 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

No studies found 1 · 11.1%GRADE not reported 0 · 0%Very low 7 · 77.8%Low 0 · 0%Moderate 1 · 11.1%High 0 · 0%

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

It is very uncertain whether vitamin K antagonist (VKA) prophylaxis changes symptomatic deep vein thrombosis compared with no prophylaxis (very low certainty).

1 finding from 1 review

Aspirin vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review

Aspirin vs vitamin K antagonist (VKA)

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether aspirin (ASA) changes symptomatic deep vein thrombosis compared with vitamin K antagonist (VKA) (very low certainty).

2 findings from 1 review

Vitamin K antagonists vs low molecular weight heparin

Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents

It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).

2 findings from 1 review